3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry

Analytica Chimica Acta

Volumn 827, Issue , 2014, Pages 54-63

  Anizan, Sebastien ^a   Ellefsen, Kayla ^a,b   Concheiro, Marta ^a   Suzuki, Masaki ^c,d   Rice, Kenner C ^c   Baumann, Michael H ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

HRMS; LC MS MS; MDPV; Metabolites; Synthetic cathinones

Indexed keywords

BIOMOLECULES; BODY FLUIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHENOLS; PLASMA (HUMAN);

CATHINONES; DOPAMINE TRANSPORTERS; HRMS; LC-MS/MS; LIQUID CHROMATOGRAPHY-HIGH RESOLUTION MASS SPECTROMETRIES; MDPV; PROTEIN PRECIPITATION; SELECTIVITY AND SENSITIVITY;

METABOLITES;

3,4 DIHYDROXYPYROVALERONE; 3,4 METHYLENEDIOXYPYROVALERONE; 4 HYDROXY 3 METHOXYPYROVALERONE; CATHINONE; RECREATIONAL DRUG; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; PYRROLIDINE DERIVATIVE;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); HUMAN; HYDROLYSIS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; THAWING; VALIDATION STUDY; ANIMAL; BLOOD; CHEMISTRY; METABOLISM; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL;

MUSCOVY DUCK PARVOVIRUS; RATTUS;

ANIMALS; BENZODIOXOLES; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROLYSIS; LIMIT OF DETECTION; LINEAR MODELS; MALE; MASS SPECTROMETRY; PYRROLIDINES; RATS; REPRODUCIBILITY OF RESULTS;

EID: 84900414552     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.04.015     Document Type: Article

References (29)

1. Emerson T.S., Cisek J.E. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Annals of Emergency Medicine 1993, 22:1897-1903.
2. German C.L., Fleckenstein A.E., Hanson G.R. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sciences 2013.
3. Kelly J.P. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis 2011, 3(7-8):439-453.
4. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. Journal of Medical Toxicology 2012, 8(1):33-42.
5. Kesha K., Boggs C.L., Ripple M.G., Allan C.H., Levine B., Jufer-Phipps R., Doyon S., Chi P., Fowler D.R. Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature. Journal of Forensic Sciences 2013.
6. Yohannan J.C., Joseph J., Bozenko S. The characterization of 3,4-methylenedioxypyrovalerone (MDPV). Microgram Journal 2010, 7(1):12-15.
7. Zawilska J.B., Wojcieszak J. Designer cathinones-an emerging class of novel recreational drugs. Forensic Science International 2013, 231(1-3):42-53.
8. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical Toxicology (Philadelphia) 2011, 49(6):499-505.
9. Borek H.A., Holstege C.P. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Annals of Emergency Medicine 2012, 60(1):103-105.
10. Kyle P.B., Iverson R.B., Gajagowni R.G., Spencer L. Illicit bath salts: not for bathing. Journal of the Mississippi State Medical Association 2011, 52(12):375-377.
11. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Chaboz S., Hoener M.C., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. British Journal of Pharmacology 2013, 168(2):458-470.
12. Cameron K.N., Kolanos R., Solis E., Glennon R.A., De Felice L.J. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. British Journal of Pharmacology 2013, 168(7):1750-1757.
13. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Rothman R.B., Goldberg S.R., Lupica C.R., Sitte H.H., Brandt S.D., Tella S.R., Cozzi N.V., Schindler C.W. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 2013, 38(4):552-562.
14. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botre F. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry 2010, 24(18):2706-2714.
15. Meyer M.R., Du P., Schuster F., Maurer H.H. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. Journal of Mass Spectrometry 2010, 45(12):1426-1442.
16. Heffe W. Die STEVENS - umlagerung von allyl-phenacyl-ammoniumsalzen. Helvetica Chimica Acta 1964, 47(5):1289-1292.
17. Meltzer P.C., Butler D., Deschamps J.R., Madras B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. Journal of Medicinal Chemistry 2006, 49(4):1420-1432.
18. Concheiro M., Anizan S., Ellefsen K., Huestis M.A. Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Analytical and Bioanalytical Chemistry 2013, 405(29):9437-9448.
19. Krouwer J.S., Rabinowitz R. How to improve estimates of imprecision. Clinical Chemistry 1984, 30(2):290-292.
20. Chesher D. Evaluating assay precision. Clinical Biochemist Reviews 2008, 29(Suppl 1):S23-S26.
21. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003, 75(13):3019-3030.
22. Scheidweiler K.B., Ladenheim B., Barnes A.J., Cadet J.L., Huestis M.A. (±)-3,4-Methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. Journal of Analytical Toxicology 2011, 35(7):470-480.
23. Mueller M., Kolbrich-Spargo E., Peters F., Huestis M., Ricaurte G., Maurer H. Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma. Analytical and Bioanalytical Chemistry 2009, 393(6-7):1607-1617.
24. Wang C.C., Hartmann-Fischbach P., Krueger T.R., Wells T.L., Feineman A.R., Compton J.C. Rapid and sensitive analysis of 3,4-methylenedioxypyrovalerone in equine plasma using liquid chromatography-tandem mass spectrometry. Journal of Analytical Toxicology 2012, 36(5):327-333.
25. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Science International 2011, 210(1-3):195-200.
26. Marinetti L.J., Antonides H.M. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. Journal of Analytical Toxicology 2013, 37(3):135-146.
27. Segura M., Ortuno J., Farre M., McLure J.A., Pujadas M., Pizarro N., Llebaria A., Joglar J., Roset P.N., Segura J., de la Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chemical Research in Toxicology 2001, 14:1203-1208.
28. Mueller M., Peters F.T., Ricaurte G.A., Maurer H.H. Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2007, 855(2):262-270.
29. Johnson R.D., Botch-Jones S.R. The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions. Journal of Analytical Toxicology 2013, 37(2):51-55.